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Introduction
Early-onset scoliosis (EOS) is defined as a coronal curvature of the spine exceeding
10° occurring before the age of 10 years, and can be subcategorized as congenital,
idiopathic, syndromic, or neuromuscular.1–4 Left untreated, EOS may progress to produce disfigurement and deformity of the chest wall, leading to thoracic insufficiency
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Purpose: Treating early-onset scoliosis (EOS) with traditional growing rods (TGR) is effective
but requires periodic surgical lengthening, risking complications. Alternatives include magnetically controlled growing rods (MCGR) that lengthen noninvasively and the growth guidance
system (GGS), which obviate the need for active, distractive lengthenings. Previous studies have
reported promising clinical effectiveness for GGS; however the direct medical costs of GGS
compared to TGR and MCGR have not yet been explored.
Methods: To estimate the cost of GGS compared with MCGR and TGR for EOS an economic
model was developed from the perspective of a US integrated health care delivery system. Using
dual-rod constructs, the model estimated the cumulative costs associated with initial implantation, rod lengthenings (TGR, MCGR), revisions due to device failure, surgical-site infections,
device exchange, and final spinal fusion over a 6-year episode of care. Model parameters were
from peer-reviewed, published literature. Medicare payments were used as a proxy for provider
costs. Costs (2016 US$) were discounted 3% annually.
Results: Over a 6-year episode of care, GGS was associated with fewer invasive surgeries per
patient than TGR (GGS: 3.4; TGR: 14.4) and lower cumulative costs than MCGR and TGR,
saving $25,226 vs TGR. Sensitivity analyses showed that results were sensitive to changes in
construct costs, rod breakage rates, months between lengthenings, and TGR lengthening setting of care.
Conclusion: Within the model, GGS resulted in fewer invasive surgeries and deep surgical site
infections than TGR, and lower cumulative costs per patient than both MCGR and TGR, over a
6-year episode of care. The analysis did not account for family disruption, pain, psychological
distress, or compromised health-related quality of life associated with invasive TGR lengthenings,
nor for potential patient anxiety surrounding the frequent MCGR lengthenings. Further analyses
focusing strictly on current generation technologies should be considered for future research.
Keywords: early-onset scoliosis, cost analysis, growth guidance system, magnetically controlled
growing rod, traditional growing rod
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syndrome characterized by labored breathing, extreme
breathlessness/fatigue, and reduced quality of life.3 Treatment
options for EOS include observation, casting, bracing, and
surgical techniques.3 Ideally EOS treatment would permit
correction (partial or complete) of the deformity, maintain
the deformity correction, and permit vertical growth of the
spine and radial expansion of the rib cage. Fusion surgeries
result in iatrogenic limitation of spinal growth with long-term
impairment of pulmonary volumes, making these surgeries
suboptimal in EOS.5 Hence “growth-friendly” surgeries
such as growth guidance system (GGS), magnetically controlled growing rods (MCGR), and traditional growing rods
(TGR) have been developed to attempt to satisfy the goals
of treatment.
TGR are effective, yet require periodic invasive surgical
lengthenings with risk of complications.6 The surgeries inherent with TGR treatment are also associated with considerable
socioeconomic, psychological, and health-related quality of life
(HRQoL) disadvantages for both patients and their caregivers.7
MCGR have also been shown to be clinically effective and can
be lengthened noninvasively, with a hand-held external remote
controller, allowing for magnetically controlled continuous
elongation (to a set tension), or incremental elongation (to a set
distance).7–12 Although device costs for MCGR are higher, several studies have shown that these may be offset by the reduced
complications and costs garnered by noninvasive lengthenings.13–16 Both TGR and MCGR are effective for preventing
disease progression and facilitating correction of curves.8–10,12,17,18
An alternative construct for EOS, GGS (SHILLA™
Growth Guidance System, Medtronic Spinal & Biologics,
Memphis, TN, USA) was cleared for marketing in the United
States in July 2014.19 GGS is a new growth-sparing technology that helps provide deformity correction while allowing
continued skeletal growth at the proximal and distal construct
ends and obviating the need for periodic lengthening procedures. GGS utilizes a unique non-locking set screw that
allows the pedicle screws to slide along the rod axis during
vertical growth. Once implanted during a surgical procedure
similar to TGR and MCGR, GGS has demonstrated clinical
effectiveness (in both curve correction and increasing thoracic height) with 6-year follow-up.20,21 Obviating the need for
invasive lengthening procedures, GGS would be expected to
reduce overall costs per patient in a similar manner to MCGR;
however, no economic study of GGS has been published to
date. The objective of this research was to estimate – over
a 6-year episode of care – the cumulative cost of treating
EOS with GGS compared with MCGR and TGR from the
US integrated health care delivery system (IDS) perspective.
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Materials and methods
Model overview
Similar to the cost analysis by Polly et al14 comparing MCGR
with TGR, the present economic model was developed from
the IDS perspective. For each treatment using dual-rod
constructs, the model assessed the 6-year cumulative costs
associated with initial implantation, rod lengthenings (TGR
every 6 months; MCGR every 3 months), revisions due to
device failure, surgical site infections (SSIs), device exchange
(at 3.8 years), and final spinal fusion. Costs are presented
in 2016 US$ and, in line with the recommendation of the
Congressional Budget Office, were discounted at an annual
rate of 3.0%.22 An institutional review board (IRB) exemption
was granted given that model parameters were sourced from
peer-reviewed, published literature and the present research
did not involve human subjects.
For the present study, the cost analysis by Polly et al14
was first reconstructed (from the publicly available paper and
technical report) and then updated to reflect the most recent
published literature and to include GGS. As such, the model
assumptions and parameter values for TGR and MCGR are
largely based on Polly et al with the exception of updating the
construct type (to 100% dual-rod to reflect current practice),
device failure rates, deep SSI rates, time under anesthesia,
and reimbursement codes and costs. For completeness, we
have summarized the assumptions and data sources in the
following section.

Model assumptions and data sources
Table 1 details the model framework created and clinical
parameters used, while medical resources are detailed in
Table 2. Importantly, the TGR device failure rates (rod
breakage rates) were derived from an economic evaluation
commissioned by the National Institute for Health and Care
Excellence,18,23 while the MCGR and GGS rod breakage rates
were obtained from the most recent comparable literature
available from multicenter studies.11,20 The device failure rates
for TGR and MCGR were corrected using the relative risk
of rod breakage for single vs dual-rods to estimate what the
rate would be if every construct were a dual-rod construct
(constructs were 64% and 85% dual-rod [P Hosseini and J
Pawelek, San Diego Spine Foundation, personal communication, April, 2017] in the sources used for TGR and MCGR,
respectively).11,18,23,24 The source used for the GGS rod breakage rate already reflected 100% dual-rod construct.20
The model assumes GGS, MCGR, and TGR are of equal
clinical effectiveness and that medical resource use for initial
implantations, revisions, and exchanges with GGS, MCGR,

ClinicoEconomics and Outcomes Research 2018:10

Dovepress

Growth guidance system vs growing rod cost analysis

Table 1 Model framework and clinical parameters
Parameter

ClinicoEconomics and Outcomes Research downloaded from https://www.dovepress.com/ by 128.252.79.225 on 18-Apr-2018
For personal use only.

Model framework
Time horizon (years)
Size of cohort
Payer mix
Private payer (%)
Medicaid (%)
Discount rate (% per annum)
TGR lengthening setting of care
Hospital outpatient/inpatient (%)
Hospital inpatient 1-day short stay (%)
Hospital inpatient standard ward (%)
Hospital inpatient ICU (%)
MCGR lengthening setting of care
Physician office (%)
GGS HCP visit setting of care
Physician office (%)
Device failuresb and SSIs
TGR device failure (% per month)
MCGR device failure (% per month)
GGS device failure (% per month)
Device failure, dual vs single rod (RR)
Device failures requiring complete removal (vs partial) (%)
TGR deep SSI (% per invasive surgery)
MCGR deep SSI (% per invasive surgery)
GGS deep SSI (% per invasive surgery)
SSI: Medicaid patients (vs all other patients) (RR)

Base case value
(sensitivity analysis [range])

Reference

6 (1–6)
Per patient
Per 1,000 patients

14, 20
NA

51.5 (0–100)
48.5 (0–100)
3.00 (0.00–5.00)

25, 26
22

45.8 (0–100)/54.2 (100–0)
55.5
35.2
9.3

14
14
14

100.0

a

100.0

a

0.55 (0.27–1.10)
0.56 (0.28–1.13)
0.61 (0.30–1.21)
0.92 (0.46–1.00)
5.8 (2.9–11.6)
2.99 (1.49–5.97)
1.45 (0.72–2.90)
2.24 (1.12–4.48)
2.06 (1.19–3.58)

18, 23, 24
11, 24
20
24
14, 24
27
11
28
29

Notes: aClinical advisors. bRod breakage.
Abbreviations: GGS, growth guidance system; HCP, health care professional; ICU, intensive care unit; MCGR, magnetically controlled growing rod; NA, not applicable; RR,
relative risk; SSI, surgical site infection; TGR, traditional growing rod.

Table 2 Resource use
Parameter

Base case value
(sensitivity analysis [range])

Reference

Months between TGR lengthenings
Months between MCGR lengthenings
Months between GGS HCP visits
Years to implant exchange
Implantation
Wedding band use for TGR (% of surgeries)
Tandem connector use for TGR (% of surgeries)
Cross link use for TGR (% of surgeries)
Cross link use for MCGR (% of surgeries)
Cross link use for GGS (% of surgeries)
Partial revision (TGR, MCGR, GGS)
Pedicle screw/hook replacement (% of surgeries)
Rod set screws replacement (% of surgeries)
All other components (% of surgeries)

6.0 (6–12)
3.0 (1–6)
6.0 (3–9)
3.8 (3–5)

17
18, 23
30
31, 32

28.0
67.0
86.0
86.0
100.0

14
14
14
14
30

95.0
61.0
100.0

14, 24a
14, 24a
14, 24a

Note: aClinical advisors.
Abbreviations: GGS, growth guidance system; HCP, health care professional; MCGR, magnetically controlled growing rod; TGR, traditional growing rod.

and TGR is similar (with the exception of anesthesia time
and device cost, where appropriate). The model also assumes
that one radiograph is required per insertion, health care
ClinicoEconomics and Outcomes Research 2018:10

p rofessional (HCP) visit (GGS), lengthening procedure
(MCGR and TGR), exchange, revision, deep SSI, and final
fusion; and treatment of deep SSIs will require intravenous
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antibiotics and a complete replacement of implants while
treatment of superficial infections will require oral antibiotics. As the cost of oral antibiotics would be incurred by the
patient (rather than the provider), this has not been included
in the analysis; there is also no consideration of pediatric
mortality. Using the average observed spinal growth in a
child with EOS aged 6 years; the model estimates that all
patients will require one surgery to exchange the device at
3.8 years.31,32
The components that require replacement during the
course of a partial revision procedure (Table 2) were based on
the TGR study by Bess et al and expert clinical advice.14,24 In
the absence of such data for GGS and MCGR, these percentages have been assumed to be the same for GGS, MCGR, and
TGR. Hence, during a partial removal for GGS, MCGR, or
TGR, pedicle screw/hooks were assumed to require replacement in 95% of surgeries, rod set screws in 61% of surgeries,
and all other components (including rods and connectors) in
100% of surgeries.
MCGR rod costs were not included for revisions due to
MCGR failure within 1 year following an MCGR implantation or MCGR exchange (in the unlikely event of a manufacturing defect); all other costs for the MCGR revisions were
included (for example, cross link, hospital facility costs, and
professional fees).
Medicare payments were used as a proxy for provider
costs (a widely accepted methodology for cost analyses).33 As
such, hospital inpatient facility costs were based on Medicare
diagnosis-related group (DRG) data, physician professional
fees were based on current procedural terminology (CPT)
data, and hospital outpatient facility costs were based on
ambulatory payment classification (APC) data. As hospital

inpatient DRG payments are bundled to include the TGR
device cost, such inpatient procedures for GGS and MCGR
had the TGR device costs subtracted and the GGS or MCGR
device costs added in order to account for the differences in
device costs. Table 3 details the total costs used for these
procedures in the model, while the Supplementary materials
detail the component costs, including all CPT, APC, and DRG
codes and costs, as well as anesthesia, intraoperative neurophysiological monitoring, and radiograph codes and costs.
Sensitivity and scenario analyses were conducted to
assess whether the cost analysis results were robust to modifications in the values of important parameters such as device
failure rates, time between lengthenings, and construct costs.

Results
Base-case results
For a single patient over the 6-year episode of care, GGS
was associated with fewer invasive surgeries than TGR and
comparable invasive surgeries to MCGR (GGS: 3.4; MCGR:
3.4; TGR: 14.4). Simulating 1,000 patients with EOS over the
6-year episode of care, deep SSIs were substantially lower
for GGS and MCGR than for TGR (GGS: 83; MCGR: 75;
TGR: 652), whereas rod breakages per 1,000 patients were
slightly lower for MCGR and TGR than for GGS (GGS: 436;
MCGR: 406; TGR: 395).
Figure 1 illustrates the cumulative costs for treatment of
EOS with GGS compared with MCGR and TGR, detailing
the higher cost of initial insertion and exchange (at 3.8 years)
for GGS being offset by the cost of frequent TGR surgical
lengthenings and associated deep SSIs. From the IDS perspective, the 6-year cumulative cost for GGS was lower than
TGR, saving US$25,226.

Table 3 Total costs used in the model (2016 US$)
Parameter
Construct
Insertiond
Lengthening
HCP visit
Exchanged
Complete revisiond
Partial revisiond
Deep SSId
Removal and final fusion

Base case values (sensitivity analysis [range])
TGR

MCGR

GGSa

15,229
(11,421–19,036)c
36,653
6,466e
NA
13,519
13,519
12,276
13,519
38,272

47,716
(35,787–59,645)c
69,140
270
NAf
46,007
46,007
44,763
46,007
38,272

33,456b
(25,092–41,820)c
55,054
NA
272
31,746
31,746
30,503
31,746
39,330

Notes: aClinical advisors. bMedtronic Spinal & Biologics. cConstruct sensitivity analysis ranges are ±25%. dConstruct costs included. eWeighted mean of inpatient and
outpatient procedures. fPhysician professional fee is included above in MCGR lengthening in the physician office. Data from Polly et al.34
Abbreviations: GGS, growth guidance system; HCP, health care professional; MCGR, magnetically controlled growing rod; NA, not applicable; SSI, surgical site infection;
TGR, traditional growing rod.
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Year
GGS
1

US$58,974

MCGR

US$71,964
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TGR

US$52,275

GGS
2

US$61,731

MCGR

US$76,022

TGR

US$66,836

GGS
3

US$64,406

MCGR

US$79,957

TGR

US$80,959
US$96,708

GGS
4

MCGR

US$126,006

TGR

US$101,096
US$99,225

GGS
5

US$128,032

MCGR

US$114,385

TGR

6

US$135,440

GGS
MCGR

US$165,356
US$160,666

TGR
US$40,000

US$0

US$80,000

US$120,000

US$200,000

US$160,000

Insertion

Lengthening/scheduled visits

Exchange

Partial revision

Complete revision

Deep SSI

Removal and final fusion
Figure 1 Cumulative cost per patient (2016 US$) over six-year episode of care.
Abbreviations: GGS, growth guidance system; MCGR, magnetically controlled growing rods; SSI, surgical site infection; TGR, traditional growing rods.

Sensitivity analysis
One-way sensitivity analyses indicated that results were
sensitive to changes in construct costs, rod breakage rates,
months between lengthenings (TGR and MCGR), and
TGR lengthening setting of care (Figures 2 and 3). Only
one parameter in the sensitivity analysis (months between
lengthenings for TGR) produced a positive budget impact for
GGS, suggesting that GGS is likely to be cost saving over a
6-year episode of care from the IDS perspective. Note that
GGS becomes cost neutral with TGR if TGR lengthenings
occur at approximately every 9 months.
Using clinically realistic scenarios, two-way sensitivity
analysis for particularly impactful and less precisely known
model parameters, specifically 1) GGS with TGR or MCGR
device failure rates, and 2) months between GGS HCP visits
with months between TGR or MCGR lengthenings, demonstrated that the cumulative costs varied by relatively little,

ClinicoEconomics and Outcomes Research 2018:10

suggesting that the economic model is robust to plausible
parameter values (Tables 1 and 2 show ranges). Only when
TGR lengthenings are performed at 9-month or greater intervals is there a positive budget impact, suggesting that GGS
is likely to be cost saving over the 6-year episode of care.
Scenario analyses (that is, multi-way sensitivity analyses)
were also run, to further assess the device failure rate (rod
breakage rate) – first all the rates for all three technologies
were set to 0.5493% per month, to reflect the adjusted, dualrod rate for TGR from The National Institute for Health and
Care Excellence (NICE) external assessment report and the
longest follow-up for the greatest number of patients.18,23 This
had a minimal impact on costs, reducing the 6-year cumulative costs for GGS and MCGR by less than 1%. The second
scenario analysis set the values for TGR and MCGR to the
lowest found in published literature and the GGS to the highest (GGS: 0.6053% [represents dual-rod construct]; MCGR:
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Percentage of TGR outpatient lengthenings
GGS construct cost
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Months between TGR lengthenings
Years until exchange
GGS device failure rate (rod breakage)
TGR construct cost
TGR deep SSI rate
TGR device failure rate (rod breakage)
Percentage of medicaid patients
Months between GGS HCP visits

GGS less
expensive than TGR

–US$60,000 –US$40,000 –US$20,000

0

US$20,000

Figure 2 One-way sensitivity analysis of cumulative cost savings per patient (GGS vs TGR; 2016 US$)
Abbreviations: GGS, growth guidance system; HCP, health care professional; SSI, surgical site infection; TGR, traditional growing rods.

Upper bound value

Lower bound value

MCGR construct cost
GGS construct cost
GGS device failure rate (rod breakage)
MCGR device failure rate (rod breakage)
Months between MCGR lengthenings
Years until exchange
MCGR deep SSI rate
Months between GGS HCP visits
GGS deep SSI rate
Annual discount rate

GGS less expensive
than MCGR

–US$60,000

–US$40,000

GGS more expensive
than MCGR

–US$20,000

0

US$20,000

Figure 3 One-way sensitivity analysis of cumulative cost savings per patient (GGS vs MCGR; 2016 US$)
Abbreviations: GGS, growth guidance system; HCP, health care professional; MCGR, magnetically controlled growing rods; SSI, surgical site infection.

0.3188% [after adjusting for 100% dual-rod construct]; TGR:
0.3905% [after adjusting for 100% dual-rod construct]). This
reduced the 6-year cumulative costs for MCGR by approximately 3% and for TGR by 1%; however, GGS remained cost
saving compared to both MCGR and TGR.

Discussion
Modeling is a simplified representation of the real world in
an analytical framework to help decision-makers (patients,
providers, and payers) compare alternative options in terms
of their clinical benefit and cost. The present study addresses
the growing need to demonstrate how medical technologies
fit into the emerging value-based paradigm. To this end, a
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model was developed to evaluate the clinical-economic value
of GGS compared to TGR and MCGR.
The economic model presented in this study demonstrates
that the cost impact of GGS due to increased construct cost
(vs TGR) and slightly higher revision rate due to device
failure (vs TGR and MCGR) is offset by obviating the need
for repeated surgeries to lengthen TGR (with associated
deep SSIs). The reduction in costs was mainly driven by
the absence of inpatient stay, anesthesia, and intraoperative
neurophysiological monitoring associated with invasive TGR
lengthenings. As seen in Figure 1, GGS becomes cost saving in the second year following implantation and remains
so throughout the remainder of the 6-year episode of care.

ClinicoEconomics and Outcomes Research 2018:10
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Hence, despite the added expense of the GGS construct
compared to the TGR construct, the cost offsets for GGS from
obviating the need for repeated surgical lengthenings with
risk of complications appear to financially justify use of GGS.
Of note, substituting the original values from the Polly et al
paper and technical appendix into this model provides very
similar costs to those reported in Polly et al, only differing
by ~1.5%; while the number of deep SSIs, invasive surgeries,
and device failures per thousand patients align perfectly.14 This
suggests that the model employed is reproducible.
Compared to MCGR, GGS had a similar number of
device failures (rod fractures) and deep SSIs; however the
reduced construct cost for GGS drove cost savings at implantation and exchange as well as after a device failure or deep
SSI. Previous economic analyses showed cost savings or cost
neutrality for MCGR vs TGR, which could be reflective of
the shorter time horizon with lack of exchange,13,16 or the less
expensive single-rod construct used in 15% of patients.14 We
believe that our approach is most reflective of current practice
with dual-rod construct and represents a realistic 6-year time
horizon, considering the average length of treatment.
As a cost analysis, rather than cost-effectiveness analysis,
this model did not account for family disruption, pain, psychological distress, implications of multiple anesthetics, or
compromised HRQoL associated with invasive TGR lengthenings, nor for patient anxiety surrounding the frequent MCGR
lengthenings. Additionally, recent literature has reported that
an increased number (eight or more) of invasive surgeries in
patients with TGR is significantly correlated with an even higher
rate of complications.27 There could therefore be substantial
additional direct and indirect cost savings associated with the
use of GGS compared to TGR. Further, the model does not
include instances where the MCGR rod fails to lengthen (as
reported by Choi et al in two of 54 patients), possibly underestimating costs of revision surgery; current recommendations
are to reattempt lengthening at a later date and if that fails,
replacing the device.11,12 Lastly, due to conflicting views on the
necessity of revision for hook dislodgement and screw pull-out
complications, these have not been included in the model. While
revision costs may therefore be slightly underestimated, they
currently only account for 9.1%, 7.5%, and 2.8% of total costs
for GGS, MCGR, and TGR, respectively, and slight variations
are unlikely to affect the budget impact trend of the model.
Also noteworthy, the Centers for Medicare and Medicaid
Services (CMS) approved MCGR for a new technology addon payment (NTAP) for fiscal year (FY) 2017 in the amount
of US$15,750, whereby CMS provides incremental payment
(in addition to the DRG payment) for technologies that qualify

ClinicoEconomics and Outcomes Research 2018:10
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for NTAP.35 The NTAP payment mechanism is based on the
cost to hospitals for the new technology and lasts for 2–3 years
until data are available to reflect the cost of the technology
in the DRG weights through recalibration. However, NTAP
applies only to Medicare patients, of whom <2,000 are under
18 years, meaning that it is unlikely that a Medicare patient
would be diagnosed with EOS, a disease that affects fewer
than one in 10,000 people.36,37 For this reason, and the fact that
CMS is proposing to discontinue NTAP for MCGR for FY
2018, we did not account for the NTAP in this cost analysis.35

Limitations
While the model parameter values were based on the most
recent published literature, these reports nevertheless reflect
various rod materials and diameters. This is particularly relevant for TGR, for which 3.5, 4.5, and 5.5 mm rods of steel
and titanium in both single- and dual-rod constructs were
reported in the NICE external assessment report.18,23 This
limitation was addressed by adjusting the TGR rod fracture
rate using the relative risk of rod fracture for single- vs dualrod construct reported by Bess et al.24 Further, the data used
herein for MCGR represented a mixture of both first- and
second- generation devices, whereby the second generation incorporates structural and mechanism improvements
intended to reduce device failures. These MCGR data also
had a limited length of follow-up (mean of 19.4 months) and a
slightly smaller population (54 patients) than that reported for
MCGR in the NICE external assessment report (80 patients
across eight studies) but was taken from a multicenter study
of five centers, rather than a collection of smaller studies
and had a higher proportion of dual-rod constructs better
reflecting current practice.11,18,23 The relatively short followup compared to GGS (6 years) and TGR (4 years) may have
inflated the MCGR device failure rate slightly.
Similarly, compared to the original GGS technique that
used 3.5 mm rods through 2008, the current GGS technique
uses larger rods, deeper screw placement, c-clamps to prevent migration in the event of rod breakage, and O-arm or
other image guidance. The rod breakage rate for GGS came
from a relatively small sample size (18 patients); however
these data were chosen because they are the most reflective
of current practice and patients were followed for six years
through definitive treatment.20 While the GGS device failure
rate represents a key model parameter, to which the cumulative costs are sensitive, it is important to note that the overall
trend of the results (a negative budget impact for GGS), does
not change in the scenario and sensitivity analysis, when
these rates are varied across a clinically relevant set of values.
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Conclusion
From the perspective of the US IDS, GGS can be cost saving over the 6-year episode of care by obviating the need
for repeated and costly invasive TGR surgical lengthenings
and their associated complications, particularly deep SSIs.
Compared with MCGR, GGS can be cost saving due to a
comparable rod fracture and deep SSI rate and a substantially
reduced construct cost. Further analyses focusing strictly on
current generation technologies and accounting for HRQoL
of children and their caregivers should be considered for
future research.
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